To compare the levels of endocannabinoids (EC) in plasma, aqueous humor and tears, cortisol in plasma and aqueous, in primary angle closure glaucoma (PACG) and controls, while comparing the quality of life in both groups.
Methods
A total of 60 patients, ≥40years of age, with a diagnosis of PACG or cataract, 30 in each group were recruited. They were subjected to a detailed ophthalmic evaluation, a WHO Quality of Life Brief Version (WHOQOL-BREF) questionnaire answering and collection of tear, aqueous and blood samples. The levels of endocannabinoids–anandamide (AEA), 2-arachidonoylglycerol (2AG) in plasma, aqueous humor and tears; cortisol in plasma and aqueous humor; and WHO-QOL score in each group were noted.
Results
Plasma AEA (p = 0.01) and plasma 2-AG, (p = 0.002) levels were significantly higher in the control group as compared to the PACG group. WHO-QOL score was better in controls (p < 0.001). The EC were in undetectable levels in aqueous. Plasma and aqueous cortisol were significantly higher in PACG and both had the highest Area under the receiver operating characteristics (AUROC) curve value for differentiating PACG from controls. Tear 2AG and tear AEA had a moderately strong positive correlation with plasma 2-AG. Females had insignificantly higher levels of plasma and tear endocannabinoids.
Conclusions
Tear endocannabinoids were determined for the first time in PACG and normal with no difference between the two groups. Plasma and aqueous cortisol levels are a differentiating factor between normal and glaucoma patients with plasma endocannabinoids being remarkably higher in normals. Quality of life in glaucoma patients with high cortisol levels is poorer.
CairnsEABaldridgeWHKellyMEM. The endocannabinoid system as a therapeutic target in glaucoma. Neural Plast2016; 2016: 9364091. doi: https://doi.org/10.1155/2016/9364091
3.
ChenJMatiasIDinhT, et al.Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun2005; 330: 1062–1067. doi: https://doi.org/10.1016/j.bbrc.2005.03.095
4.
MatiasIWangJWMorielloAS, et al.Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukot Essent Fatty Acids2006; 75: 413–418. doi: https://doi.org/10.1016/j.plefa.2006.08.002
5.
PorcellaACasellasPGessaGL, et al.Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain Res Mol Brain Res1998; 58: 240–245. doi: https://doi.org/10.1016/s0169-328x(98)00105-3
6.
BisognoTDelton-VandenbrouckeIMiloneA, et al.Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys1999; 370: 300–307. doi: https://doi.org/10.1006/abbi.1999.1410
7.
StraikerAJMaguireGMackieK, et al.Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci1999; 40: 2442–2448.
8.
StraikerAStellaNPiomelliD, et al.Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc Natl Acad Sci U S A1999; 96: 14565–14570. doi: https://doi.org/10.1073/pnas.96.25.14565
PorcellaAMaxiaCGessaGL, et al.The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur J Neurosci2000; 12: 1123–1127. doi: https://doi.org/10.1046/j.1460-9568.2000.01027.x
12.
StamerWDGolightlySFHosohataY, et al.Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol2001; 431: 277–286. doi: https://doi.org/10.1016/s0014-2999(01)01438-8
13.
LópezEMTagliaferroPOnaiviES, et al.Distribution of CB2 cannabinoid receptor in adult rat retina. Synap N Y N2011; 65: 388–392. doi: https://doi.org/10.1002/syn.20856
14.
MallipedhiAPriorSLDunseathG, et al.Changes in plasma levels of N-arachidonoyl ethanolamine and N-palmitoylethanolamine following bariatric surgery in morbidly obese females with impaired glucose homeostasis. J Diabetes Res2015; 2015: 680867. doi: https://doi.org/10.1155/2015/680867
15.
AbdulnourJYasariSRabasa-LhoretR, et al.Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. Obes Silver Spring Md2014; 22: 211–216. doi: https://doi.org/10.1002/oby.20498
16.
RichardsonPOrtoriCBarrettD, et al.Endocannabinoids in aqueous humour of patients with or without diabetes. BMJ Open Ophthalmol2020; 5: e000425. doi: https://doi.org/10.1136/bmjophth-2019-000425
17.
PavlenkoTAKimARKurinaAY, et al.Endothelins and dopamine levels in tears for assessment of neurovascular disorders in glaucoma. Vestn Oftalmol2018; 134: 41–46. doi: https://doi.org/10.17116/oftalma201813404141
18.
PavlenkoTAChesnokovaNBDavydovaHG, et al.Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy. Vestn Oftalmol2013; 129: 20–23.
19.
McCartyGRSchwartzB. Reduced plasma cortisol binding to albumin in ocular hypertension and primary open-angle glaucoma. Curr Eye Res1999; 18: 467–476. doi: https://doi.org/10.1076/ceyr.18.6.467.5264
20.
SchwartzBMcCartyGRosnerB. Increased plasma free cortisol in ocular hypertension and open angle glaucoma. Arch Ophthalmol Chic Ill 19601987; 105: 1060–1065. doi: https://doi.org/10.1001/archopht.1987.01060080062029
WilsonMRColemanALYuF, et al.Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology2002; 109: 1018–1022. doi: https://doi.org/10.1016/s0161-6420(02)00993-4
23.
YochimBPMuellerAEKaneKD, et al.Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma. J Glaucoma2012; 21: 250–254. doi: https://doi.org/10.1097/IJG.0b013e3182071b7e
24.
Ibarra-LecueIPilar-CuéllarFMuguruzaC, et al.The endocannabinoid system in mental disorders: evidence from human brain studies. Biochem Pharmacol2018; 157: 97–107. doi: https://doi.org/10.1016/j.bcp.2018.07.009
25.
HodappEParrishRAndersonD. Clinical decisions in glaucoma. Mosby: St. Louis, MO, 1993.
26.
ThomasAHopfgartnerGGiroudC, et al.Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom RCM2009; 23: 629–638. doi: https://doi.org/10.1002/rcm.3918
FlachsbarthKKruszewskiKJungG, et al.Neural stem cell-based intraocular administration of ciliary neurotrophic factor attenuates the loss of axotomized ganglion cells in adult mice. Invest Ophthalmol Vis Sci2014; 55: 7029–7039. doi: https://doi.org/10.1167/iovs.14-15266
29.
ShpakAAGuekhtABDruzhkovaTA, et al.Ciliary neurotrophic factor in patients with primary open-angle glaucoma and age-related cataract. Mol Vis2017; 23: 799–809.
30.
PieragostinoDBucciSAgnifiliL, et al.Differential protein expression in tears of patients with primary open angle and pseudoexfoliative glaucoma. Mol Biosyst2012; 8. doi: https://doi.org/10.1039/c1mb05357d
31.
CongdonNGYoulinQQuigleyH, et al.Biometry and primary angle-closure glaucoma among Chinese, white, and black populations. Ophthalmology1997; 104: 1489–1495. doi: https://doi.org/10.1016/s0161-6420(97)30112-2
32.
FosterPJ. The epidemiology of primary angle closure and associated glaucomatous optic neuropathy. Semin Ophthalmol2002; 17: 50–58. doi: https://doi.org/10.1076/soph.17.2.50.14718
33.
SihotaRAgarwalHC. Profile of the subtypes of angle closure glaucoma in a tertiary hospital in north India. Indian J Ophthalmol1998; 46: 25–29.
34.
DasJBhomajSChaudhuriZ, et al.Profile of glaucoma in a major eye hospital in north India. Indian J Ophthalmol2001; 49: 25–30.
35.
NucciCGasperiVTartaglioneR, et al.Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci2007; 48: 2997–3004. doi: https://doi.org/10.1167/iovs.06-1355
36.
SlusarJECairnsEASzczesniakA-M, et al.The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy. Neuropharmacology2013; 72: 116–125. doi: https://doi.org/10.1016/j.neuropharm.2013.04.018
37.
MillerSLeishmanEHuSS, et al.Harnessing the endocannabinoid 2-arachidonoylglycerol to lower intraocular pressure in a murine model. Invest Ophthalmol Vis Sci2016; 57: 3287–3296. doi: https://doi.org/10.1167/iovs.16-19356
38.
CraftRMMarusichJAWileyJL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?Life Sci2013; 92: 476–481. doi: https://doi.org/10.1016/j.lfs.2012.06.009
39.
RozsívalPHamplRObenbergerJ, et al.Aqueous humour and plasma cortisol levels in glaucoma and cataract patients. Curr Eye Res1981; 1: 391–396. doi: https://doi.org/10.3109/02713688109019976
40.
DzhodzhuaTSumbadzeT. Pituitary-adrenal axis system condition in patients with open angle glaucoma. Georgian Med News2005; 126: 74–76.
41.
SchmidtDCKesselLBach-HolmD, et al.Prevalence and risk factors for hypothalamus-pituitary-adrenal axis suppression in infants receiving glucocorticoid eye drops after ocular surgery. Acta Ophthalmol (Copenh)2023; 101: 229–235. doi: https://doi.org/10.1111/aos.15253
42.
SuC-CChenJY-CWangT-H, et al.Risk factors for depressive symptoms in glaucoma patients: a nationwide case-control study. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol2015; 253: 1319–1325. doi: https://doi.org/10.1007/s00417-015-3032-0
43.
HillMNMillerGECarrierEJ, et al.Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology2009; 34: 1257–1262. doi: https://doi.org/10.1016/j.psyneuen.2009.03.013
